Intarcia Therapeutics, a US-based biopharmaceutical firm whose name is derived from the Latin for insert, has nearly doubled the equity it has raised over the past 15 years with its latest $160m round. Intarcia said its combined $160m sale of shares and $50m debt placement was “the largest sum to be raised by a private…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
